Investigational Treatment Options in Relapse ANLL

Abstract • 183

Chemotherapy of primary ANLL is intensive and may include an allogeneic or autologous stem cell infusion (SCI). Still about 50% of the patients will relapse. Treatment results of these patients are dismal and their tolerance for further chemotherapy is limited. Therefore, alternative novel treatment options should be investigated such as: 1) phase II cytostatic drugs like cladribine (2-CDA), fludarabine, liposomal daunorubicin; 2) combinations of cytostatic drugs with multi drug resistance reversing agents like cyclosporin; 3) growth factors to increase chemosensitivity of the leukemic cells or to ameliorate myelosuppression; 4) immunotherapy with donor lymphocyte infusions (after allogeneic SCI), with interleukin 2 (IL-2), or cytotoxic antibodies; 5) after achieving second complete remission a (second) allogeneic SCI from the same or an other donor (matched unrelated or haplo-identical); 6) differentiation enhancers like all-transretinoic acid (ATRA) and butyric acid derivatives. Obviously, these investigational approaches should be used only within a collaborative study. The protocol should allow for the heterogeneity of the relapse ANLL patients. Treatment of relapse ANLL patients not registered on a study protocol is not in the patient's best interest and may be considered unethical.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tamminga, R., de Bont, E. Investigational Treatment Options in Relapse ANLL. Pediatr Res 45, 773 (1999). https://doi.org/10.1203/00006450-199905010-00213

Download citation